Cancer survival, time to cure for survivor (5 years vs. 10 years)
Progression of undetected cancer (calibrated baseline parameter set vs. alternative parameter set)
Colposcopy age-standardised attendance (75% vs. perfect)
Unsatisfactory cytology rate (4.4% vs. 1.1%)
Colposcopy test characteristics (baseline assumption vs. perfect accuracy)
CIN3 to invasive cancer progression rate (0.8% p.a. vs. 2.6% p.a.)
Cytology test characteristics (various alternate test characteristics (2))
Screening initiation (baseline age-specific initiation vs. all commenced at age 20)
HPV incidence (halved vs. doubled)
Re-screening compliance after 4th year (perfect compliance vs. baseline assumption)
Re-screening compliance after 5th year (perfect compliance vs. baseline assumption)
Re-screening compliance after 10 years (0.3 p.a. in all ages vs. 0.3 p.a. in 10-69 years and 0 p.a. in 70+ years)
Early re-screening (1)
Re-screening compliance after 4th year (perfect compliance vs. baseline assumption)
Pre-cancer natural history (less aggressive parameter set vs. more aggressive parameter set)
Unsatisfactory cytology rate (4.4% vs. 1.1%)
Screening initiation (baseline age-specific initiation vs. all commenced at age 20)
Cytology test characteristics (baseline assumption vs. perfect accuracy)
CIN3 to invasive cancer progression rate (0.8% p.a. vs. 2.6% p.a.)
Colposcopy test characteristics (baseline assumption vs. perfect accuracy)
Unsatisfactory cytology rate (4.4% vs. 1.1%)
Colposcopy age-standardised attendance (75% vs. perfect)
Progression of undetected cancer (calibrated baseline parameter set vs. alternative parameter set)
Cancer survival, time to cure for survivor (5 years vs. 10 years)